World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
70
Citations
16904
World Ranking
7026
National Ranking
3234

Overview

Richard S. Geary is affiliated with Ionis Pharmaceuticals in the United States. Their work spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a primary focus on molecular biology and cardiovascular and metabolic diseases.

The scientist's research covers various subfields including Molecular Biology, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Genetics, and Surgery. Their main topics of work involve:

  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • RNA Interference and Gene Delivery
  • DNA and Nucleic Acid Chemistry
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Advanced biosensing and bioanalysis techniques
  • Lipid metabolism and disorders
  • Lipoproteins and Cardiovascular Health

Frequent publication venues for the scientist include:

  • Nucleic Acid Therapeutics
  • Journal of the American Society of Nephrology
  • European Heart Journal
  • New England Journal of Medicine
  • Circulation

Frequent co-authors collaborating with Richard S. Geary include:

  • Sotirios Tsimikas
  • Eugene Schneider
  • Brett P. Monia
  • Sanjay Bhanot
  • Rosie Z. Yu

Recent notable papers authored or co-authored by Richard S. Geary are:

  • Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia, 2020, European Heart Journal
  • Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk, 2021, European Heart Journal
  • An oral antisense oligonucleotide for PCSK9 inhibition, 2021, Science Translational Medicine
  • Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial, 2020, The Lancet Gastroenterology & Hepatology
  • Antisense drug discovery and development technology considered in a pharmacological context, 2020, Biochemical Pharmacology

Best Publications

  • Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

    Richard S. Geary;Daniel Norris;Rosie Yu;C. Frank Bennett

  • Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

    Nicholas J Viney;Julian C van Capelleveen;Richard S Geary;Shuting Xia

  • Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

    Mark J. Graham;Richard G. Lee;Teresa A. Brandt;Li-Jung Tai

  • Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

    Sotirios Tsimikas;Sotirios Tsimikas;Nicholas J Viney;Steven G Hughes;Walter Singleton

  • Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

    Daniel Gaudet;Veronica J. Alexander;Brenda F. Baker;Diane Brisson

  • Targeting APOC3 in the Familial Chylomicronemia Syndrome

    Daniel Gaudet;Diane Brisson;Karine Tremblay;Veronica J. Alexander

  • Volanesorsen and triglyceride levels in familial chylomicronemia syndrome

    Joseph L Witztum;Daniel Gaudet;Steven D Freedman;Veronica J Alexander

  • Pharmacology of Antisense Drugs

    C. Frank Bennett;Brenda F. Baker;Nguyen Pham;Eric Swayze

  • Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

    Mark J. Graham;Richard G. Lee;Thomas A. Bell;Wuxia Fu

  • Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats

    Richard S. Geary;Tanya A. Watanabe;LoAnne Truong;Sue Freier

  • Antisense oligonucleotide pharmacokinetics and metabolism.

    Richard S Geary

  • Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100

    Rosie Z. Yu;Tae-Won Kim;An Hong;Tanya A. Watanabe

  • Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

    Maartje E. Visser;Gilbert Wagener;Brenda F. Baker;Richard S. Geary

  • Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.

    Yuen Ar;Halsey J;Fisher Ga;Holmlund Jt

  • Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.

    Daniel Gaudet;Ewa Karwatowska-Prokopczuk;Seth J Baum;Eunju Hurh

  • Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

    J. Nemunaitis;J. T. Holmlund;M. Kraynak;D. Richards

  • Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

    Stanley T. Crooke;Richard S. Geary

  • Compounds and methods for modulating gene expression

    Sanjay Bhanot;Richard S. Geary;Robert Mckay;Brett P. Monia

  • Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.

    R S Geary;R Z Yu;A A Levin

  • Fomivirsen: clinical pharmacology and potential drug interactions.

    Richard S. Geary;Scott P. Henry;Lisa R. Grillone

Frequent Co-Authors

Sotirios Tsimikas
Sotirios Tsimikas University of California, San Diego
Rosanne M. Crooke
Rosanne M. Crooke Ionis Pharmaceuticals (United States)
Eric E. Swayze
Eric E. Swayze Ionis Pharmaceuticals (United States)
Brett P. Monia
Brett P. Monia Ionis Pharmaceuticals (United States)
Punit P. Seth
Punit P. Seth Ionis Pharmaceuticals (United States)
Joseph L. Witztum
Joseph L. Witztum University of California, San Diego
Stanley T. Crooke
Stanley T. Crooke Ionis Pharmaceuticals (United States)
Daniel Gaudet
Daniel Gaudet University of Montreal
Erik S.G. Stroes
Erik S.G. Stroes University of Amsterdam
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can lead to diverse healthcare careers. Many students are choosing online programs for flexibility and affordability. For example, those interested in nutrition can review the cost of masters degree in nutrition to compare schools and find affordable options.

The medical imaging sector is another in-demand pathway. With the rise of ultrasound tech school online programs, it's easier than ever to train for roles like diagnostic medical sonographer without attending traditional classes. Many programs cater to working professionals, letting you balance study and work.

If you're drawn to radiology, consider enrolling in accelerated radiology tech programs online. These programs provide a fast-track to certification and entry-level positions in healthcare imaging.

Dietetics is a growing career for those passionate about health and nutrition science. Specialized dietetic masters programs offer advanced training to help graduates stand out in clinical, community, and food service settings.

Whether you're starting your career or upskilling, online degrees open new doors to exciting biology and healthcare roles.

Best Scientists Citing Richard S. Geary

Trending Scientists

Recently Published Articles